Search results for "Myocardial ischemia"

showing 10 items of 106 documents

Increased prevalence of cardiac arrhythmias and transient episodes of myocardial ischemia in hypertensives with left ventricular hypertrophy but with…

1997

To evaluate the behavior of cardiac arrhythmias (CA) and transient episodes of myocardial ischemia (TEMI), in relation to the circadian pattern of blood pressure in patients suffering from arterial hypertension, with or without echocardiographically ascertained left ventricular hypertrophy (LVH), we studied 128 patients, 87 men (M) and 41 women (F), aging from 21 to 76 years, subdivided into two groups: Group I, including 66 patients with LVH (45 M and 21 F; mean age of 53.7 ± 9.1 years; Group II, including 62 patients without LVH ( 42 M and 20 F; mean age of 49.7 ± 9.5 years). Office blood pressure (OBP) as well as nighttime ambulatory blood pressure (ABP) were higher in patients with LVH …

AdultMalemedicine.medical_specialtyAmbulatory blood pressureHeart diseasePremature atrial contractionMyocardial IschemiaBlood PressureCoronary DiseaseVentricular tachycardiaLeft ventricular hypertrophyElectrocardiographyHeart RateInternal medicineHeart rateInternal MedicinemedicineHumanscardiovascular diseasesAgedbusiness.industryArrhythmias CardiacBlood Pressure Monitoring AmbulatoryMiddle Agedmedicine.diseaseEchocardiography DopplerCircadian RhythmBlood pressureHypertensioncardiovascular systemCardiologyFemaleHypertrophy Left VentricularSupraventricular tachycardiabusinessAmerican journal of hypertension
researchProduct

Effects of drug therapy on cardiac arrhythmias and ischemia in hypertensives with LVH.

2001

Left ventricular hypertrophy (LVH) in hypertensive subjects is associated with an increased prevalence of ventricular arrhythmias. To evaluate the effect of antihypertensive treatment on cardiac arrhythmias (CA) and transient episodes of myocardial ischemia (TEMI), we studied 46 hypertensive patients with LVH, divided into four groups randomly treated with enalapril, hydrochlorothiazide (HCTZ), atenolol, or verapamil (SR-V) for 6 months. Office blood pressure and office heart rate values were recorded, in basal conditions, after 1 and 6 months of treatment, and all patients underwent echocardiography, electrocardiographic Holter monitoring, and stress testing. All drugs significantly lowere…

AdultMalemedicine.medical_specialtyHeart diseaseMyocardial IschemiaBlood PressureLeft ventricular hypertrophyHydrochlorothiazideEnalaprilInternal medicineHeart rateInternal MedicinemedicineHumanscardiovascular diseasesEnalaprilAntihypertensive AgentsAgedmedicine.diagnostic_testbusiness.industryArrhythmias CardiacMiddle Agedmedicine.diseaseAtenololBlood pressureHydrochlorothiazideTreatment OutcomeAtenololVerapamilHypertensioncardiovascular systemCardiologyElectrocardiography AmbulatoryFemaleHypertrophy Left VentricularbusinessElectrocardiographyAnti-Arrhythmia Agentsmedicine.drugAmerican journal of hypertension
researchProduct

Correlation between mortality trends of ischaemic cardiopathy and some nutritional factors in Spain 1968?1986

1992

After describing the evolution of mortality from ischaemic cardiopathy (IC) in Spain from 1951 to 1986, which is tending to stabilize in some age groups, and from cerebrovascular accidents (CVA), which is clearly declining, an attempt is made to relate these developments to the prevalence of the main risk factors (hypertension, cholesterol, tobacco) associated with IC and CVA. Certain advances, though of a limited number, have been made in recent years in the control of arterial hypertension in Spain, although campaigns on a national scale as in other countries have not been carried out. Regarding alimentary factors, there is an obvious increase in the consumption of food rich in proteins a…

AdultMalemedicine.medical_specialtyPediatricsMeatTime FactorsAdolescentMediterranean dietEpidemiologyNutrition EducationMyocardial IschemiaRisk FactorsEnvironmental healthVegetablesEpidemiologyHealth caremedicineHumansRisk factorMortality trendsConsumption (economics)business.industryPublic healthSmokingDietary FatsDietCerebrovascular DisordersSpainFemalebusinessEuropean Journal of Epidemiology
researchProduct

Advantages of immediate two-dimensional echocardiography in patients with acute cardiac ischemic events

1995

Abstract We hypothesized that the assessment of kinetic alterations on two dimensional echocardiogram (2DE) would provide greater diagnostic information than clinical symptoms and ECG changes only. The study was aimed to determine sensitivity of 2DE in patients with cardiac ischemic events and to improve the indications to thrombolysis. Three-hundred ninety-one patients (87 F; 304 M) hospitalized for suspected acute myocardial infarction (AMI), first episode, within 4 h from the onset of symptoms, suitable for thrombolysis Killip class I–II and with unstable angina (UA), were admitted in the study. Patients had to show ECG changes and alterations of segmentary motion on 2DE performed at ent…

AdultMalemedicine.medical_specialtySystolemedicine.medical_treatmentMyocardial InfarctionMyocardial IschemiaIschemiaInfarctionSensitivity and SpecificityVentricular Function LeftElectrocardiographyFibrinolytic AgentsInternal medicinemedicineHumansThrombolytic TherapyAngina Unstablecardiovascular diseasesMyocardial infarctionAngioplasty Balloon CoronaryCoronary Artery BypassCreatine KinaseAgedKillip classAged 80 and overFirst episodeHeparinVascular diseaseUnstable anginabusiness.industryThrombolysisMiddle Agedmedicine.diseaseIsoenzymesSurvival RateEchocardiographyVentricular Function RightCardiologyFemaleCardiology and Cardiovascular MedicinebusinessInternational Journal of Cardiology
researchProduct

Immediate versus delayed facilitated percutaneous coronary intervention. A pilot study

2005

The study was aimed to investigate the outcomes in patients initially successfully treated pharmacologically and immediate PCI <2 hours, and in patients initially successfully treated with pharmacological therapy and delayed PCI (12-72 hours). All patients had to have successful reperfusion, to receive the combination of a standard abciximab infusion plus half dose rtPA. Similar results were observed in both groups. Delayed PCI group showed a favorable trend in restenosis and bleedings (ns) and a significant reduced angiographic evidence of thrombus formation in IRA. Our very preliminary data suggest the safety and possible use of delayed facilitated PCI in patients with STEMI. The studied …

AdultMalemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentAbciximabMyocardial InfarctionMyocardial IschemiaEligibility DeterminationMyocardial ReperfusionPilot ProjectsAcute myocardial infarctionElectrocardiographyImmunoglobulin Fab FragmentsRestenosisInternal medicinemedicineAbciximabHumansIn patientcardiovascular diseasesThrombusAngioplasty Balloon CoronaryFacilitated pciDelayed percutaneous coronary interventionPharmacologybusiness.industryPatient SelectionPercutaneous coronary interventionAntibodies MonoclonalMiddle Agedmedicine.diseaseSurvival RateGIIb/IIIa inhibitorssurgical procedures operativeTreatment OutcomeTissue Plasminogen ActivatorConventional PCICardiologyFemaleCardiology and Cardiovascular MedicinebusinessFacilitated percutaneous coronary interventionTIMIPlatelet Aggregation InhibitorsCombined therapymedicine.drug
researchProduct

Cardiovascular events among reproductive and menopausal age women with polycystic ovary syndrome: a systematic review and meta-analysis

2019

This study aimed to evaluate the prevalence (P)/hazard ratio (HR) of cardiovascular (CV) events among reproductive age and menopausal age women with polycystic ovary syndrome (PCOS) in comparison with healthy controls. PubMed, Scopus, ScienceDirect, Web of science, and Google scholar were searched for retrieving observational studies published up to April 2018 investigating CV events in patients with PCOS. The primary outcomes were a composite outcome of CV events [including coronary arterial disease (CAD), cardiovascular disease (CVD), myocardial infarction (MI), angina, heart failure, and ischemic heart disease] and mortality due to CV events; secondary outcomes were specific CVD events, …

Adultmedicine.medical_specialtyEndocrinology Diabetes and MetabolismPopulationMyocardial InfarctionMyocardial Ischemia030209 endocrinology & metabolismCoronary Artery DiseaseAngina PectorisAngina03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicinePrevalencemedicineHumansMyocardial infarctionRisk factoreducationAgedProportional Hazards ModelsHeart Failureeducation.field_of_study030219 obstetrics & reproductive medicinebusiness.industryPolycystic ovary syndrome (PCOS)Hazard ratioObstetrics and GynecologyMiddle Agedmedicine.diseasePolycystic ovaryStrokeCerebrovascular DisordersCardiovascular DiseasesCase-Control StudiesFemalebusinessPolycystic Ovary SyndromeCohort studyGynecological Endocrinology
researchProduct

Application of C1-Esterase Inhibitor During Reperfusion of Ischemic Myocardium

2001

Background—Complement activation during reperfusion of ischemic myocardium augments myocardial injury, and complement inhibition with C1-esterase inhibitor (C1-INH) at the time of reperfusion exerts marked cardioprotective effects in experimental studies. Application of C1-INH in newborns, however, was recently reported to have dangerous and even lethal side effects. This study addresses the essential role of dosage in studies using C1-INH.Methods and Results—Cardioprotection by C1-INH was examined in a pig model with 60 minutes of coronary occlusion followed by 120 minutes of reperfusion. C1-INH was administered intravenously 5 to 10 minutes before coronary reperfusion without heparin at a…

Anaphylatoxinsmedicine.medical_specialtyNecrosisSwineHeart VentriclesPartial PressureMyocardial IschemiaIschemiaComplement C1 Inactivator ProteinsPharmacologyNecrosisTroponin TCoronary CirculationPhysiology (medical)Internal medicineAnimalsMedicineLactic AcidMyocardial infarctionCardiac OutputCreatine KinaseCardioprotectionDose-Response Relationship Drugbiologybusiness.industryMyocardiumHemodynamicsHeparinmedicine.diseaseComplement systemOxygenMicroscopy ElectronEndocrinologyCoronary occlusionEnzyme inhibitorReperfusion Injurybiology.proteinBlood Gas Analysismedicine.symptomCardiology and Cardiovascular Medicinebusinessmedicine.drugCirculation
researchProduct

Transmural myocardial ischaemia complicating recovery after dobutamine-atropine stress echocardiography in patients with non-significant coronary art…

2011

In the proposed selection of cases, traditional imaging is integrated with contemporary diagnostic tools available in the cath-lab to navigate the potential mechanisms underlying a very rare complication occurring in the recovery phase of dobutamine-atropine stress echocardiography. The data, collected in a time frame of nearly 15 years, provide interesting elements to possibly evolve from speculative considerations to plausible confirmation of the candidate pathophysiological mechanism mediating the occurrence of transmural myocardial ischaemia after beta-blockers administration.

AtropineMaleChest Painmedicine.medical_specialtyMyocardial ischaemiamedicine.drug_classAdrenergic beta-AntagonistsMyocardial IschemiaCoronary Artery DiseaseCoronary AngiographyCoronary artery diseaseElectrocardiographyInternal medicineStress EchocardiographyHumansMedicineRadiology Nuclear Medicine and imagingBeta blockerAgedbusiness.industryParasympatholyticsGeneral MedicineMiddle Agedmedicine.diseaseFractional Flow Reserve MyocardialAtropineCardiologyFemaleDobutamineCardiology and Cardiovascular MedicinebusinessComplicationCoronary physiologyEchocardiography Stressmedicine.drugEuropean Journal of Echocardiography
researchProduct

Safety and feasibility of atropine added in patients with sub-maximal heart rate during exercise myocardial perfusion SPECT.

2006

Failure to reach 80% of maximal predicted heart rate (HR) during exercise may render a myocardial perfusion single photon emission computed tomography (SPECT) study non-diagnostic for ischemia detection. We sought to investigate the injection of atropine in patients who fail to achieve 80% of age-predicted HR during exercise performed for myocardial perfusion SPECT (MPS), defining its safety and efficacy to raise HR to adequate levels as well as its effect on MPS interpretation.Between January 2002 and December 2004, we studied 3,150 consecutive patients (2,253 men and 897 women, mean age 55 +/- 6 years) who were referred to a single office-based nuclear cardiology laboratory for MPS using …

AtropineMalemedicine.medical_specialtyIschemiaMyocardial IschemiaBlood PressureSingle-photon emission computed tomographySeverity of Illness IndexMetabolic equivalentCholinergic AntagonistsOrganophosphorus CompoundsHeart RateInternal medicineSpect imagingCoronary CirculationHeart rateMedicineHumansRadiology Nuclear Medicine and imagingTomography Emission-Computed Single-Photonexercise testingmedicine.diagnostic_testmaximal predicted heart ratebusiness.industrymyocardial perfusion SPECTArrhythmias CardiacOrganotechnetium CompoundsMiddle Agedmedicine.diseaseAtropineRate pressure productResearch DesignCardiologyExercise TestFeasibility StudiesFemaleRadiopharmaceuticalsCardiology and Cardiovascular MedicinebusinessPerfusionmedicine.drugThe international journal of cardiovascular imaging
researchProduct

Increased Platelet Sensitivity toward Platelet Inhibitors during Physical Exercise in Patients with Coronary Artery Disease

1999

Generalized atherosclerosis and coronary artery disease (CAD) are associated with endothelial dysfunction and during acute myocardial ischemia platelet activation has been reported. Activated platelets exert activated fibrinogen receptors (GP IIb/IIIa) and express CD 62p being regarded as reliable marker for platelet activation. Patients with angiographically proven CAD performed a bicycle exercise test until the onset of angina or ST-segment depression. We studied the ischemia-induced alterations in fibrinogen binding to activated platelet GP IIb/IIIa receptors and CD 62p expression. Therefore, the basal fibrinogen binding to GP IIb/IIIa and CD 62p expression and the thrombin-concentration…

Blood Plateletsmedicine.medical_specialtyMyocardial IschemiaCoronary DiseaseProstacyclinPlatelet Glycoprotein GPIIb-IIIa ComplexNitric OxideFibrinogenThrombinRisk FactorsInternal medicinemedicineHumansPlateletcardiovascular diseasesPlatelet activationEndothelial dysfunctionbusiness.industryThrombinFibrinogen bindingHematologyMiddle AgedPlatelet Activationmedicine.diseaseEpoprostenolRadiographyP-SelectinEndocrinologyExercise TestCardiologybusinessPlatelet Aggregation Inhibitorsmedicine.drugIloprostThrombosis Research
researchProduct